Treatment with ribociclib plus endocrine therapy led to a statistically and clinically meaningful improvement in invasive disease-free survival among patients with hormone receptor–positive/HER2-negative early breast cancer compared with endocrine therapy alone, meeting the primary end point of the phase 3 NATALEE trial.
The immune landscape for low and intermediate estrogen receptor-positive breast tumors appears to mimic that for triple-negative tumors, suggesting a potential role for immunotherapy.
Suzanne B. Coopey, MD, FACS, discusses the de-escalation of axillary lymph node surgery, shifts in the use of radiation oncology, and changes in the treatment paradigm for HER2-positive breast cancer.
Ribociclib plus switch endocrine therapy induced a statistically significant progression-free survival benefit compared with placebo plus switch endocrine therapy in patients with hormone receptor–positive, HER2-negative, metastatic breast cancer.